{"id":"W2725925241","doi":"10.1111/bjh.14820","title":"Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab <i>versus</i> chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma","year":2017,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Pfizer","keywords":"Rituximab; Medicine; Calicheamicin; Internal medicine; Oncology; Hazard ratio; Interim analysis; Refractory (planetary science); CD22; Clinical endpoint; Aggressive lymphoma; Lymphoma; CD20; Clinical trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002892653,0.001942108,0.002823818,0.000416761,0.0005338541,0.001563504,0.001132197,0.001475753,0.005655257],"category_scores_gemma":[0.001709819,0.0009154833,0.002080364,0.0003763942,0.001463578,0.001308788,0.0005409363,0.004649254,0.001215095],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001336496,"about_ca_system_score_gemma":0.00170352,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00141417,"about_ca_topic_score_gemma":0.004492153,"domain_scores_codex":[0.9990987,0.000526832,0.00004010538,0.0001454022,0.00005923896,0.0001298262],"domain_scores_gemma":[0.9988781,0.000269281,0.0002605538,0.0001150915,0.00006840138,0.0004086675],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9820371,0.006801816,0.0002912714,0.0002107504,0.0005578116,0.00002745938,0.00004376617,0.0003262897,0.002518197,0.0001288516,0.0009174399,0.00613918],"study_design_scores_gemma":[0.9364002,0.06074459,0.0008877438,0.0000143451,0.0002769906,0.00002382521,0.00001576626,0.000476849,0.0003061224,0.0002238296,0.0006169484,0.00001286409],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9759889,0.002521457,0.001249089,0.001105655,0.001129432,0.01109863,0.002280461,0.0002852326,0.004341235],"genre_scores_gemma":[0.9735675,0.001827858,0.003587571,0.00268899,0.0006425912,0.01042568,0.00243091,0.00007681621,0.004752147],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005655257,"threshold_uncertainty_score":0.01891875,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02536001530919176,"score_gpt":0.3144805966185323,"score_spread":0.2891205813093406,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}